Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Accured Expenses: 2017-2025

Historic Change in Accured Expenses for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $6.6 million.

  • Crinetics Pharmaceuticals' Change in Accured Expenses rose 866.13% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 147.08%. This contributed to the annual value of $17.5 million for FY2024, which is 19.75% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $6.6 million for Q3 2025, which was down 46.89% from $12.5 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Change in Accured Expenses registered a high of $12.5 million during Q2 2025, and its lowest value of -$1.4 million during Q1 2025.
  • For the 3-year period, Crinetics Pharmaceuticals' Change in Accured Expenses averaged around $4.5 million, with its median value being $4.4 million (2023).
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Change in Accured Expenses plummeted by 369.23% in 2022, and later soared by 866.13% in 2025.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Change in Accured Expenses stood at $3.9 million in 2021, then climbed by 4.75% to $4.1 million in 2022, then climbed by 2.65% to $4.2 million in 2023, then skyrocketed by 146.72% to $10.3 million in 2024, then surged by 866.13% to $6.6 million in 2025.
  • Its Change in Accured Expenses was $6.6 million in Q3 2025, compared to $12.5 million in Q2 2025 and -$1.4 million in Q1 2025.